Paula Green Sells 1,259 Shares of Twist Bioscience Co. (NASDAQ:TWST) Stock

Twist Bioscience Co. (NASDAQ:TWST) SVP Paula Green sold 1,259 shares of the stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $49.35, for a total transaction of $62,131.65. Following the completion of the sale, the senior vice president now owns 132,014 shares of the company’s stock, valued at approximately $6,514,890.90. The trade was a 0.94 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Paula Green also recently made the following trade(s):

• On Friday, January 3rd, Paula Green sold 160 shares of Twist Bioscience stock. The shares were sold at an average price of $45.59, for a total value of $7,294.40.
• On Friday, December 20th, Paula Green sold 282 shares of Twist Bioscience stock. The shares were sold at an average price of $44.90, for a total value of $12,661.80.
• On Friday, December 6th, Paula Green sold 860 shares of Twist Bioscience stock. The stock was sold at an average price of $52.70, for a total value of $45,322.00.
• On Monday, November 11th, Paula Green sold 1,347 shares of Twist Bioscience stock. The stock was sold at an average price of $48.00, for a total value of $64,656.00.

Twist Bioscience Stock Performance

Shares of TWST stock traded up $1.64 on Wednesday, hitting $53.66. The company’s stock had a trading volume of 942,523 shares, compared to its average volume of 781,392. Twist Bioscience Co. has a fifty-two week low of $27.41 and a fifty-two week high of $60.90. The company has a market capitalization of $3.19 billion, a PE ratio of -14.91 and a beta of 1.87. The stock’s 50 day moving average is $48.63 and its 200-day moving average is $46.21.

Twist Bioscience (NASDAQ:TWST) last announced its earnings results on Monday, February 3rd. The company reported ($0.53) EPS for the quarter, topping the consensus estimate of ($0.62) by $0.09. The company had revenue of $88.70 million for the quarter, compared to analysts’ expectations of $86.96 million. Twist Bioscience had a negative net margin of 66.69% and a negative return on equity of 32.27%. The business’s revenue for the quarter was up 24.1% on a year-over-year basis. During the same period last year, the firm earned ($0.75) earnings per share. On average, research analysts forecast that Twist Bioscience Co. will post -2.27 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on TWST. JPMorgan Chase & Co. increased their target price on Twist Bioscience from $35.00 to $40.00 and gave the company an “underweight” rating in a research note on Tuesday. Leerink Partners boosted their price objective on shares of Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a research report on Thursday, October 17th. Barclays cut their target price on Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 19th. Scotiabank increased their target price on Twist Bioscience from $54.00 to $62.00 and gave the stock a “sector outperform” rating in a research note on Tuesday. Finally, TD Cowen reissued a “buy” rating and issued a $58.00 price objective on shares of Twist Bioscience in a research report on Tuesday, November 26th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, Twist Bioscience currently has a consensus rating of “Moderate Buy” and a consensus price target of $53.80.

Institutional Trading of Twist Bioscience

A number of institutional investors have recently modified their holdings of the stock. Van ECK Associates Corp raised its stake in Twist Bioscience by 56.4% in the fourth quarter. Van ECK Associates Corp now owns 740 shares of the company’s stock valued at $34,000 after purchasing an additional 267 shares in the last quarter. Wilmington Savings Fund Society FSB bought a new position in Twist Bioscience in the 3rd quarter valued at about $34,000. Signaturefd LLC raised its position in shares of Twist Bioscience by 63.0% in the 3rd quarter. Signaturefd LLC now owns 792 shares of the company’s stock valued at $36,000 after buying an additional 306 shares in the last quarter. US Bancorp DE lifted its holdings in shares of Twist Bioscience by 72.0% during the 4th quarter. US Bancorp DE now owns 1,436 shares of the company’s stock worth $67,000 after acquiring an additional 601 shares during the period. Finally, Beaird Harris Wealth Management LLC acquired a new stake in shares of Twist Bioscience during the 3rd quarter worth approximately $95,000.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.